Blend Therapeutics Lands $16 Million, Names a CEO
Blend Therapeutics, one-year-old pre-clinical biotech focused on oncology drugs, has raised $16 million in Series B financing and named the former head of Sunovion Pharmaceuticals as its new CEO.
Mark Iwicki was named president and CEO, and has been named to the board of directors of the Watertown company, which emerged from stealth in January. The company is based on nanoparticle technology developed by Omid Farokhzad of Brigham and Women’s Hospital (BWH) and Harvard Medical School (HMS), and Robert Langer and Dr. Stephen J. Lippard of MIT. Iwicki has more than 23 years of experience in the pharmaceutical industry, including most recently as CEO of Sunovion and CCO of Sepracor.
Mark Iwicki was named president and CEO, and has been named to the board of directors of the Watertown company, which emerged from stealth in January. The company is based on nanoparticle technology developed by Omid Farokhzad of Brigham and Women’s Hospital (BWH) and Harvard Medical School (HMS), and Robert Langer and Dr. Stephen J. Lippard of MIT. Iwicki has more than 23 years of experience in the pharmaceutical industry, including most recently as CEO of Sunovion and CCO of Sepracor.